Results 31 to 40 of about 8,134 (194)

Interventions for chronic non-hypovolaemic hypotonic hyponatraemia (Review) [PDF]

, 2018
Background : Chronic (present > 48 hours) non-hypovolaemic hyponatraemia occurs frequently, can be caused by various conditions, and is associated with shorter survival and longer hospital stays.
Craig, Jonathan C, Haller, Maria C, Nagler, Evi, Van Biesen, Wim, Vanholder, Raymond, Webster, Angela C   +5 more
core   +2 more sources

Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

BMC Nephrology, 2017
Background Tolvaptan slows progression of autosomal dominant polycystic kidney disease (ADPKD) by antagonizing the vasopressin-cAMP axis. Nitric oxide (NO) stimulates natriuresis and diuresis, but its role is unknown during tolvaptan treatment in ADPKD ...
Safa Al Therwani, My Emma Sofie Malmberg, Jeppe Bakkestroem Rosenbaek, Jesper Noergaard Bech, Erling Bjerregaard Pedersen   +4 more
doaj   +1 more source

Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan

Kidney Medicine, 2020
Rationale & Objective: Euvolemic hyponatremia often occurs due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Vasopressin 2 receptor antagonists may be used to treat SIADH.
Ramy M. Hanna, Juan Carlos Velez, Anjay Rastogi, Minhtri K. Nguyen, Mohammad K. Kamgar, Kyaw Moe, Farid Arman, Huma Hasnain, Niloofar Nobakht, Umut Selamet, Ira Kurtz   +10 more
doaj   +1 more source

Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort

Scientific Reports, 2023
Tolvaptan is the first disease-modifying drug proven to slow eGFR decline in high-risk patients with ADPKD. However, barriers from the patient perspective to its use in real-life settings have not been systemically examined in a large cohort.
Luca Calvaruso, Kevin Yau, Pedram Akbari, Fatemah Nasri, Saima Khowaja, Bill Wang, Amirreza Haghighi, Korosh Khalili, York Pei   +8 more
doaj   +1 more source

Unveiling some FDA-approved drugs as inhibitors of the store-operated Ca2+ entry pathway. [PDF]

, 2017
The store-operated calcium entry (SOCE) pathway is an important route for generating cytosolic Ca2+ signals that regulate a diverse array of biological processes.
Rahman, Saifur, Rahman, Taufiq
core   +2 more sources

Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. [PDF]

, 2020
Arginine vasopressin (AVP) and its type-2 receptor (V2R) play an essential role in the regulation of salt and water homeostasis by the kidneys. V2R activation also stimulates proliferation of renal cell carcinoma (RCC) cell lines in vitro.
Calvet, James P, Dwivedi, Nidhi, Enders, Jonathan, Jamadar, Abeda, Kakade, Vijayakumar R, Neil, Maura O', Rao, Reena, Sinha, Sonali, Tao, Shixin, Thomas, Sufi M, Weiss, Robert H   +10 more
core  

PHS48 Cost-Effectiveness Analysis of Tolvaptan for Hyponatreamia in South Korea [PDF]

, 2005
Lanz, AlfredoPla general de la part frontal de dona ajaguda sobre un suport en forma de llit o taula. Va ser donada per l'autor, Alfredo Lanz, i simbolitza el mar Mediterrani.
Kang, H.J., Choi, J., Lee, M.Y., Lee, E.K.   +3 more
core   +1 more source

Total body fluid is the factor that affects the pharmacokinetics of tolvaptan, and its efficacy, in acute worsening heart failure patients

Pharmacology Research & Perspectives, 2023
The optimal starting dose of tolvaptan to effectively improve fluid retention in patients with heart failure (HF) is unknown. This study explored the factors affecting the pharmacokinetics (PKs) and pharmacodynamics of tolvaptan in patients with ...
Takahiro Kato, Yoko Yasuda, Hitomi Okamoto, Yuji Saito, Yusuke Nakano, Katsuhiko Matsuura, Masafumi Oonishi, Tetsuya Amano   +7 more
doaj   +1 more source

Identification and Characterization of an Activating F229V Substitution in the V2 Vasopressin Receptor in an Infant with NSIAD [PDF]

, 2012
Gain-of-function mutations in the gene encoding the V2 vasopressin receptor (V2R) cause nephrogenic syndrome of inappropriate antidiuresis. To date, reported mutations lead to the substitution of arginine 137 by either a cysteine or leucine (R137C/L ...
Abrol, Ravinder, Bichet, Daniel G., Bouvier, Michel, Carpentier, Eric, Goddard, William A., III, Greenbaum, Larry A., Rochdi, Driss   +6 more
core   +1 more source

Terapia diuretica nell’insufficienza cardiaca cronica: evidenze, esperienze, prospettive = Diuretic treatment in patients with chronic heart failure: evidences, experiences, and current perspectives [PDF]

, 2017
Congestion is a fundamental clinical sign in patients with chronic heart failure (CHF). Diuretics are the mainstay treatment for congestion but, so far, no randomized trial has ever shown any beneficial effect of diuretics on mortality in patients with ...
Carubelli, Valentina, Pellicori, Pierpaolo   +1 more
core   +1 more source